Figure 6: Recurrent VEL genes maintain CRC phenotype.
From: Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome
(a) Growth-inhibition curves for a relatively sensitive (green) and a less sensitive (yellow) CRC cell line treated with JQ1 for three days (relative to day 0; mean±s.d.). (b) JQ1 doses required for 50% inhibition (IC50) for all 20 CRC lines assayed. (c) Tumor volume in mouse xenograft models treated with 25 mg kg−1 BID JQ1 (green/yellow) or DMSO control (grey) in a relatively sensitive (V457) and less sensitive (V9M) CRC line (mean±s.d.). T-test *P<0.05, **P<0.01; n=10 per group. (d) Line plots depicting fold change of expression (JQ1 treated/untreated) of various gene sets at indicated time points of JQ1 treatment (mean±s.e.m.). (e) Gene set enrichment analysis (GSEA) displaying enrichment of recurrent gained VEL genes among high-confidence fitness genes from the Toronto KnockOut library in HCT116 CRC cells (NES, normalized enrichment score).
